Skip to content

Evaluation of the efficacy of Trachyspermum ammi topical cream on neuropathy symptoms in cancer patients

Evaluation of the efficacy of Trachyspermum ammi topical cream on taxane induced peripheral neuropathy symptoms in cancer patients : a pilot study

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT20131218015860N6
Enrollment
40
Registered
2021-07-06
Start date
2021-08-23
Completion date
Unknown
Last updated
2021-07-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Neoplastic (malignant) related neuropathy. Drug-induced polyneuropathy

Interventions

Intervention 1: Intervention group: Trachyspermum Ammi and almond oil in a cream formulation at a rate of 5% of the total cream will be used. Trachyspermum Ammi essential oil (10% of the total cream)
both creams are white. Cancer patients with taxane-induced peripheral neuropathy, receiving ointment of placebo, 1 mg twice a day for four weeks.

Sponsors

Shahid Beheshti University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: Patients with cancer Patients whose neuropathy is due to chemotherapy with taxane drugs or a history of chemotherapy taxane that is a maximum of two months from completion of chemotherapy last Having symptoms of peripheral neuropathy Neuropathy is based on the diagnosis of a neurologist due to chemotherapy Aged between 18 and 80 years Willingness to collaborate in the study

Exclusion criteria

Exclusion criteria: diabetes Carpal tunnel syndrome Reluctance to stay in study Acute psychological symptoms such as depression (taking medication for it) Unforeseen treatments such as surgery, radiation therapy or immunotherapy that were not previously part of the participant's treatment plan Vitamin B6 deficiency or high (diagnosed by doctor and interview) Any signs of allergy or side effects from the drug Deterioration of the patient renal failure Brain metastasis Previous history of axilla or lumbar or pelvic radiotherapy A history of neuropathy due to other conditions that the person had before starting chemotherapy or getting cancer

Design outcomes

Primary

MeasureTime frame
Pain. Timepoint: Weeks zero and four. Method of measurement: Visual Analogue Scale.;Tingling. Timepoint: Weeks zero and four. Method of measurement: Visual Analogue Scale.;Symptoms of peripheral neuropathy. Timepoint: Weeks zero and four. Method of measurement: Chemotherapy Induced Peripheral Neuropathy Assessment Tool (CIPNAT) questionnaire.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactGhazaleh Heydarirad M.D

Shahid Beheshti University of Medical Sciences

dr.ghazalrad@sbmu.ac.ir+98 218877352

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026